en · de · es
sr9009-notes.peptides7501.com › Guide › Background And Pharmacological Mechanism — Evidence Review

Background And Pharmacological Mechanism — Evidence Review

By Editorial Desk · published 2026-08-01 · last reviewed 2026-08-01 · Guide

A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Related pages on this site

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Handling Storage and Quality Control

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Background from the literature

==== Vice President JD Vance ==== Trump's administration has also expressed cultural disagreement with Europe and the European Union: in a speech at the 61st Munich Security Conference, Vice President Vance criticized European policies on free speech and democratic values, and accused European leaders of suppressing dissenting views on issues such as immigration. Vance also expressed support for lifting restrictions on the Alternative for Germany, a far-right German political party.

IPF is believed to be the result of an aberrant wound healing process including/involving abnormal and excessive deposition of collagen (fibrosis) in the pulmonary interstitium with minimal associated inflammation. Cellular senescence is suspected to be a central contributing cause, a belief which is supported by benefits seen in patients given senolytic therapy. It is hypothesized that the initial or repetitive injury in IPF occurs to the lung alveolar epithelial cells (pneumocytes), the type I and type II cells, which line the majority of the alveolar surface. When type I cells are damaged or lost, it is thought that type II cells undergo proliferation to cover the exposed basement membranes. In normal repair, the hyperplastic type II cells die and the remaining cells spread and undergo a differentiation process to become type I cells. Under pathologic conditions and in the presence of transforming growth factor beta (TGF-β), fibroblasts accumulate in these areas of damage and differentiate into myofibroblasts that secrete collagen and other proteins. In the current classification of the pathogenesis of IPF, it is believed that it occurs by way of the formation of a UIP (usual interstitial pneumonia) lesion, which then undergoes the aforementioned pathological condition characteristic of IPF. Other proposed repeated injury mechanisms indicate that IPF may result not just from a UIP lesion, but also from NSIP and DAD (nonspecific interstitial pneumonia and diffuse alveolar damage) lesions, or a combination of several.

The four substrates of this enzyme are salicylic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton, Its products are catechol, oxidised NAD+, water, and carbon dioxide. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. This enzyme participates in metabolic pathways involving the degradation of naphthalene and anthracene and some of their derivatives. It uses flavin adenine dinucleotide as a cofactor.

A Latter-day Saint historian in Idaho talked about how previously it was controversial to donate to refugee programs in Idaho (which was attributed to a Fox News story), but a month after Kearon spoke on the subject there were five new refugee charities in Rexburg. On 1 August 2020, Kearon became the senior president of the Seventy. Prior to his appointment to the Quorum of the Twelve, Kearon spoke three times in general conference. In the first, in October 2010, he spoke of being healed spiritually through the atonement of Jesus Christ. He related a story of how he was stung by a scorpion as a child after he disregarded his parents' instruction to wear shoes in the Arabian desert and elected to wear flip flops instead. In April 2016, he spoke of church members' efforts to help refugees. In April 2022, he spoke to those who have survived abuse, violence, or oppression. On 7 December 2023, he was called and ordained an apostle, then set apart as a member of the Quorum of the Twelve Apostles, filling a vacancy created by the death of M. Russell Ballard the prior month.

=== Nationwide === 99 Speedmart AEON Group AEON AEON MaxValu Prime AEON BiG (Formerly Carrefour) DAISO AgroBazaar Econsave Giant Hypermarket KK Mart Lotus's (Formerly Tesco, Tesco Extra) Mydin Eco-Shop MR.DIY

Sources: en.wikipedia.org

Reference notes

== Chemistry == Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the hydrochloride, which is a white powder. It is synthesized by alkylating (3-methoxyphenyl)acetonitrile with bis(2-chloroethyl)methylamine, followed by reaction with ethylmagnesium bromide, and finally O-demethylation with hydrobromic acid. Because of a strong vesicant nature of bis(2-chloroethyl)methylamine there are many other routes developed for obtaining ketobemidone. A route depicted below lays through first alkylating the same (3-methoxyphenyl)acetonitrile with 2-chloro-N,N-dimethylethylamine or 2-chloro-N-benzyl-N-methylethylamine. Next, those amines are alkylated once again using a mixed 1-bromo-2-chloroethane, thus completing the piperidine ring and obtaining a quaternary ammonium salt, which can be dequaternized using thiophenol salt (for N,N-dimethylammonium) or catalytic hydrogenation (for both compounds) to a common 4-(3-methoxyphenyl)-4-cyano-1-methyl-pyperidine. The latter yields ketobemidone after Grignard reaction with ethylmagnesium bromide and ether cleavage.

The α2 receptor couples to the Gi/o protein. It is a presynaptic receptor, causing negative feedback on, for example, norepinephrine (NE). When NE is released into the synapse, it feeds back on the α2 receptor, causing less NE release from the presynaptic neuron. This decreases the effect of NE. There are also α2 receptors on the nerve terminal membrane of the post-synaptic adrenergic neuron. Actions of the α2 receptor include: decreased insulin release from the pancreas increased glucagon release from the pancreas contraction of sphincters of the GI-tract negative feedback in the neuronal synapses - presynaptic inhibition of norepinephrine release in CNS increased platelet aggregation decreases peripheral vascular resistance α2 agonists (see actions above) can be used to treat: hypertension – decrease blood pressure-raising actions of the sympathetic nervous system α2 antagonists can be used to treat: impotence – relax penile smooth muscles and ease blood flow depression – enhance mood by increasing norepinephrine secretion Subtype unspecific β agonists can be used to treat:

date-range is the range of dates corresponding to the given confidence level confidence indicates the confidence level for the given date range. For example, "cal 1220–1281 AD (1σ)" means a calibrated date for which the true date lies between AD 1220 and AD 1281, with a confidence level of '1 sigma', or approximately 68%. Calibrated dates can also be expressed as "BP" instead of using "BC" and "AD". The curve used to calibrate the results should be the latest available IntCal curve. Calibrated dates should also identify any programs, such as OxCal, used to perform the calibration. In addition, an article in Radiocarbon in 2014 about radiocarbon date reporting conventions recommends that information should be provided about sample treatment, including the sample material, pretreatment methods, and quality control measurements; that the citation to the software used for calibration should specify the version number and any options or models used; and that the calibrated date should be given with the associated probabilities for each range.

== Congresses == I National Congress – Prato, 1 March 1998 II National Congress – Trieste, 10 October 1999 III National Congress – Torino, 2 December 2001 IV National Congress – Torino, 29 October 2006 V National Congress – Villanova d'Asti, 6 November 2011 VI Congresso Nazionale - Villanova d'Asti, 30 ottobre 2016 VII Congresso Nazionale - San Paolo Solbrito, 5 giugno 2022

Barnsley Football Club is a professional football club in Barnsley, South Yorkshire, England. The club competes in EFL League One, the third tier of English football. Nicknamed “the Reds”, "the Tykes" or less commonly "the Colliers", they were founded in 1887 by Reverend Tiverton Preedy and moved to Oakwell the following year. The club's original blue colours were changed to red and white in 1904. Barnsley spent the 1890s in the Sheffield & District, Midland and Yorkshire leagues, before gaining admittance to the Football League Second Division in 1898. They twice reached the final of the FA Cup whilst still in the second tier, losing to Newcastle United in 1910 and winning the competition over West Bromwich Albion in 1912. The club suffered relegation in 1933, but secured promotion as Third Division North champions in 1934. They won the Third Division North title for a second time in 1939, having been relegated the previous season. Relegated again in 1953, they secured another Third Division North title in 1955. However, further relegations left them in the fourth tier of English football by 1966. Promotion from the Fourth Division was achieved in 1968, though they were relegated after just four seasons. The club secured two promotions in three years under the stewardship of Allan Clarke and Norman Hunter, and from 1981 would spend sixteen consecutive years in the second tier. Premier League football was secured for the 1997–98 season with a second-place finish in the First Division, though they were relegated after one season and dropped down to the third tier in 2002.

Sources: en.wikipedia.org

Notes from published material

While artesunate is used primarily as treatment for malaria, there is some evidence that it may also have some beneficial effects in Schistosoma haematobium infection, but has not been evaluated in large randomized trials. Artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinine.

==== Price regulations ==== In a bid to lower soaring gas prices, Castillo reintroduced liquefied petroleum gas (LPG) to the Fuel Price Stabilization Fund (FEPC). The FEPC was created in 2002 and serves as a price support by giving a range of minimum and maximum consumer prices. In theory, the FEPC is self-sustaining. Should the price of gas be above the maximum consumer price, the FEPC will subsidize the cost for consumers. If the price of gas is below the minimum consumer price, then the profits will be given to the FEPC. However, LPG was removed from the FEPC in 2020, due to financial costs and scepticism on whether consumer prices were affected by the fiscal intervention. The reintroduction of LPG to the FEPC by Castillo reversed the 2020 policy decision. Additionally, while Pedro Castillo's Economic Minister Pedro Francke and then Prime Minister Guido Bellido have denied any plans to institute price controls, the Free Peru caucus later attempted to modify the constitution to implement them. The amendment would have allowed the state to regulate the "supply and prices of goods and services produced by public and private companies" due to shortages or a state of emergency. However, the amendment failed to pass within the opposition-controlled Congress.

TB-500 (Ac-LKKTETQ) is a synthetic heptapeptide that corresponds to the N-acetylated active fragment (amino acids 17–23) of the endogenous signaling factor thymosin beta-4. It is claimed to increase muscle growth and accelerate wound healing and tissue repair, reduce inflammation, and improve flexibility. There is concern it could be used in sports doping. It gained attention during the 2020's uptick in off-label peptide use. It has not undergone any human trials and high levels of it are associated with tumor development. It has been encountered as a designer drug mainly in racehorses, but is also prohibited for use by athletes in competition by the World Anti-Doping Agency, and is classified as a prescription medicine in some jurisdictions such as Australia and New Zealand. N-acetylated LKKTETQ (Ac-LKKTETQ) and several of its metabolites can be detected in equine urine and plasma following administration of TB-500 using liquid chromatography–mass spectrometry, with metabolite profiling enabling identification of peptide-derived products in biological samples.

As such, whereas other TCAs can be combined with monoamine oxidase inhibitors (with caution due to the risk of hypertensive crisis from NET inhibition; sometimes done in treatment-resistant depressives), clomipramine cannot be due to the risk of serotonin syndrome and death. Unlike the case of its serotonin receptor antagonism, orthostatic hypotension is a common side effect of clomipramine, suggesting that its blockade of the α1-adrenergic receptor is strong enough to overcome the stimulatory effects on the α1-adrenergic receptor of its NET inhibition.

A 1984 study that combined selegiline with phenylalanine reported remarkably high effectiveness in the treatment of depression similar to that with electroconvulsive therapy (ECT). However, selegiline in its original oral form was never further developed or approved for the treatment of depression. A few years after the discovery that selegiline was a selective MAO-B inhibitor, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Moussa B. H. Youdim, visited Knoll in Budapest and took selegiline from him to Vienna. In 1975, Birkmayer's group published the first paper on the effect of selegiline in Parkinson's disease. Speculation, by József Knoll, that selegiline could be useful as an anti-aging and pro-sexual agent, began in the 1980s. The New York Times reported that selegiline was being used non-medically as a "smart drug" by 1992. Selegiline was first introduced for clinical use in Hungary in 1977. It was approved in the oral pill form under the brand name Jumex to treat Parkinson's disease. The drug was then introduced in the United Kingdom in 1982. In 1987, Somerset Pharmaceuticals in New Jersey, which had acquired the rights to develop selegiline in the United States, filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) to market the drug for Parkinson's disease in this country. While the NDA was under review, Somerset was acquired in a joint venture by two generic drug companies, Mylan and Bolan Pharmaceuticals.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network